Aziz Khan, MD
Hematology & Oncology · Springfield, ILNPI 1699702316
Payments from drug & device makers
What this record shows
6 manufacturers reported payments, led by Johnson & Johnson at 26.1% of the total. That places this record below the midpoint for hematology & oncology clinicians in IL, where the typical reported total is $2,365.
Across 6 payments — averaging $63.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$99
- Incyte Corporation$98
- Lilly USA, LLC$90
- Rigel Pharmaceuticals, Inc.$58
- Sanofi$23
- Gilead$12
Across 8 payments — averaging $8538.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$68K
- Merck$382
What the payments were for
- Food & beverage$17947%
- Education$20153%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 1 | $99 |
| Incyte Corporation | 1 | $98 |
| Lilly USA, LLC | 1 | $90 |
| Rigel Pharmaceuticals, Inc. | 1 | $58 |
| Sanofi | 1 | $23 |
| Gilead | 1 | $12 |
How this compares
$380 in reported general payments places this provider in the 25th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 27 | $581,490 |
| ImbruvicaIbrutinib | 25 | $407,684 |
| DopteletAvatrombopag Maleate | 15 | $352,663 |
| LenvimaLenvatinib Mesylate | 12 | $296,878 |
| BrukinsaZanubrutinib | 12 | $210,800 |
| Deferiprone (3 Times A Day)Deferiprone | 13 | $198,388 |
| IbrancePalbociclib | 13 | $196,740 |
| VenclextaVenetoclax | 15 | $176,706 |
| LonsurfTrifluridine/Tipiracil Hcl | 18 | $172,934 |
| Imatinib Mesylate | 36 | $147,563 |
| Everolimus | 12 | $115,104 |
| Abiraterone Acetate | 20 | $47,135 |
| EliquisApixaban | 31 | $28,631 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 43 | $1,071 |
| Morphine Sulfate ErMorphine Sulfate | 24 | $873 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Springfield
- Mohamad Khair KhasawnehMaywood$998K
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- John BerryBerwyn$687K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Tulio RodriguezZion$337K
- Chih-Yi LiaoChicago$317K
- Gary KayElk Grove Village$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.